Research Article
Efficacy and Safety of Surgical Ligation versus Endovascular Embolization for Type II Congenital Extrahepatic Portosystemic Shunt
Table 1
Baseline characteristics of patients in both groups.
| | Characteristic | Surgical group () | Interventional group () | value |
| | Age | | | 0.68 | | Male | 5 (38.5) | 8 (80.0) | | | Female | 8 (61.5 | 2 (20.0) | | | CEPS symptoms | | | | | Hepatic encephalopathy | 6 (46.2) | 5 (50.0) | >0.99 | | Gastrointestinal bleeding | 4 (30.8) | 2 (20.0) | 0.66 | | Dyspnea | 1 (7.7) | 0 (0) | >0.99 | | Abdominal pain | 1 (7.7) | 1 (10.0) | >0.99 | | Hepatic myelopathy | 1 (7.7) | 1 (10.0) | >0.99 | | Hemoptysis | 0 (0) | 1 (10.0) | >0.99 | | Fatigue | 2 (15.4) | 1 (10.0) | >0.99 | | Comorbidity | | | | | Hepatic cirrhosis | 10 (76.9) | 5 (50.0) | 0.22 | | Hepatic adenoma | 2 (15.4) | 0 (0) | 0.49 | | Pulmonary hypertension | 1 (7.7) | 1 (10.0) | >0.99 | | Hypersplenism | 1 (7.7) | 1 (10.0) | >0.99 | | Location of shunt vessels | | | | | Splenorenal shunt | 5 (38.5) | 3 (30.0) | >0.99 | | SMV-IVC shunt | 3 (23.1) | 1 (10.0) | 0.60 | | Portal vein-IVC shunt | 3 (23.1) | 2 (20.0) | >0.99 | | SMV-renal vein shunt | 1 (7.7) | 1 (10.0) | >0.99 | | Portal vein-renal vein shunt | 1 (7.7) | 1 (10.0) | >0.99 | | Portal vein-iliac vein shunt | 0 (0) | 2 (20.0) | 0.18 |
|
|
Data are numbers of patients, with percentages in parentheses. SMV: superior mesenteric vein; IVC: inferior vena cava.
|
